首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Medicine >The preparation of core/shell structured microsphere of multi first-line anti-tuberculosis drugs and evaluation of biological safety
【2h】

The preparation of core/shell structured microsphere of multi first-line anti-tuberculosis drugs and evaluation of biological safety

机译:多种一线抗结核药物核/壳结构微球的制备及生物安全性评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To introduce a modified method, namely coaxial electrohydrodynamic atomization for the fabrication of distinct core/shell structured microspheres of four first-line ant-tuberculosis drugs with different characteristics in hydrophilic properties in one single step. In group B, we prepared microspheres in which the core and the shell contain hydrophobic and hydrophilic drugs, respectively. In contrast, in group C, the opposite is prepared. The detection of encapsulation efficiency and in vitro release test were performed to confirm the feasibility of the drug-loaded core/shell structured microspheres. Moreover, cell culture experiments and animal experiments have been carried out to evaluate the biological safety of different microspheres in cell growth, cell viability, osteogenesis and migration of BMSCs in vitro and the bone fusion in a bone deficits model in SD rat. Meanwhile, the distribution of drugs and liver and kidney toxicity were monitored. The release patterns of the two groups are significantly different. The release of drugs from Group B microspheres is rather sequential, whereas group C microspheres release drugs in a parallel (co-release) manner. And various concentrations of carrier materials produces core/shell structured microspheres with different appearance. Moreover, the biological safety of core/shell structured microspheres was testified to be satisfactory. These findings present the advantages and possible application of this kind of multi-drug release system in treating skeletal tuberculosis. Moreover, the characteristic sequential release of multi-drugs can be controlled and adjusted based on treatment need and used in treating other disorders.
机译:要介绍一种改进的方法,即同轴电流体雾化,只需一步,即可制造出具有不同亲水特性的四种一线抗结核药物的独特核/壳结构微球。在B组中,我们制备了其中核和壳分别包含疏水性和亲水性药物的微球。相反,在C组中,准备相反的事情。进行包封效率的检测和体外释放测试,以证实载药的核/壳结构微球的可行性。此外,已经进行了细胞培养实验和动物实验,以评价不同微球在体外BMSCs的细胞生长,细胞生存力,成骨和迁移以及SD大鼠骨缺损模型中的骨融合中的生物安全性。同时,监测药物分布和肝肾毒性。两组的释放模式明显不同。从B组微球释放药物的过程是连续的,而C组微球以并行(共释放)的方式释放药物。并且各种浓度的载体材料产生具有不同外观的核/壳结构微球。此外,核/壳结构微球的生物安全性被证明是令人满意的。这些发现表明了这种多药物释放系统在治疗骨骼结核中的优势和可能的应用。此外,可以根据治疗需要来控制和调节多种药物的特征性顺序释放,并将其用于治疗其他疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号